Omeprazole (A2845): Technical Guidance for Gastric Acid Secretion Research

What This Product Solves

Omeprazole, chemically known as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, is a potent and selective H+,K+-ATPase inhibitor developed for use in preclinical models of gastric acid secretion and antiulcer activity study. Its principal value lies in the ability to reproducibly and reversibly inhibit gastric acid secretion, enabling controlled interrogation of acid-dependent physiological and pathological processes in vitro and in vivo (product_spec).

Researchers working on peptic ulcer disease models or broader gastric acid-related disorders frequently require a compound with reliable potency, solubility, and storage characteristics. Omeprazole (A2845) addresses these needs by coupling validated inhibitory activity (IC50 of 5.8 μM for H+,K+-ATPase; IC50 of 0.16 μM for histamine-induced acid formation) with robust chemical and analytical characterization. Its insolubility in water and ethanol, but high solubility in DMSO (≥17.27 mg/mL), makes it compatible with a range of cell-based and ex vivo protocols where aqueous solubility is not a primary constraint (product_spec).

To understand advanced applications and quality control nuances, see also: "Omeprazole: Precision H+,K+-ATPase Inhibition for Gastric..." for workflow optimization, and "Optimizing Gastric Acid Secretion Research with 3-(quinol..." for reproducibility guidance in cell-based and ex vivo assays.

Protocol Parameters

• assay | H+,K+-ATPase inhibition | 5.8 μM (IC50) | Use as benchmark for dose-response studies in enzymatic assays or cell-based gastric acid secretion models | Value from product_spec
• assay | Acid formation inhibition (histamine-induced) | 0.16 μM (IC50) | Guides initial concentration range for antiulcer activity study in histamine-activated models | Value from product_spec
• solubilization | DMSO | ≥17.27 mg/mL | Dissolve Omeprazole in DMSO for stock solutions; avoid water or ethanol due to insolubility | Value from product_spec
• storage | Solid at -20°C | N/A | Ensures chemical stability; avoid preparing bulk solutions for long-term storage | Value from product_spec
• working solution | Prepare fresh before use | N/A | Maintains biological activity and prevents degradation in solution | Workflow recommendation

Workflow Setup and QC Checklist

Implementing Omeprazole in gastric acid secretion research or antiulcer activity study requires attention to several procedural and quality control steps:

1. Stock Solution Preparation: Dissolve Omeprazole in DMSO at concentrations up to 17.27 mg/mL. Vortex thoroughly to ensure complete dissolution. Avoid water and ethanol as solvents due to confirmed insolubility (product_spec).
2. Aliquoting and Storage: Dispense stock solutions into single-use aliquots to minimize freeze-thaw cycles. Store the solid form at -20°C. Do not store working solutions for extended periods; prepare fresh before use.
3. Thawing and Handling: Allow aliquots to equilibrate to room temperature before dilution. Confirm solution clarity before use; discard if precipitation is observed.
4. Assay Controls: Include vehicle-only controls (DMSO) to account for solvent effects in cell-based or ex vivo assays. For dose-response work, start with concentrations bracketing the IC50 values for the relevant assay type.
5. Documentation: Record lot number, preparation date, and storage conditions for each batch used. Verify purity (approx. 98%) and molecular weight (345.42) for accurate dosing calculations.
6. Shipping and Receipt: Ensure shipment on blue ice for temperature-sensitive handling. Upon receipt, promptly transfer to -20°C storage to maintain integrity (product_spec).

Common Failure Modes and Fixes

• Incomplete Dissolution: If undissolved material remains after vortexing in DMSO, gently warm the vial (≤37°C) and vortex again. Avoid sonication, which may induce degradation.
• Precipitation in Working Dilutions: If precipitation occurs upon dilution into aqueous assay buffers, ensure the final DMSO concentration does not fall below solubility threshold; increase DMSO content if compatible with assay constraints.
• Loss of Activity: Decreased inhibitory effect may indicate compound degradation—always prepare fresh working solutions and limit time at room temperature.
• Variable Results Across Batches: Confirm purity, molecular weight, and storage history for each lot. Deviations may indicate improper storage or handling.
• Assay Interference: High DMSO concentrations may affect some cell-based assays. Titrate vehicle controls to match experimental conditions.

Scope and Limitations

Omeprazole (A2845) is intended strictly for scientific research use in the study of gastric acid secretion mechanisms, antiulcer drug development, and proton pump inhibition. It is not designed for diagnostic or clinical use, and quantitative claims are limited to the IC50 values established in the product dossier (product_spec). Applications outside gastric acid-related disorders or peptic ulcer disease model systems should be validated independently. Storage and solution handling are critical; improper procedures may result in loss of compound potency or reproducibility issues.

Conclusion

Omeprazole (SKU A2845) from APExBIO provides a technically validated, high-purity H+,K+-ATPase inhibitor for robust investigation of gastric acid secretion and antiulcer mechanisms. By adhering to defined solubilization, storage, and protocol parameters, researchers can maximize reproducibility and data quality in both mechanistic and translational models. For further procedural detail, consult the Omeprazole product specification and referenced internal workflow guides. This product should not be used outside of controlled research environments, and all usage must be documented in accordance with laboratory best practices.